Inthera Bioscience, a Swiss biopharmaceutical company developing first-in-class targeted small molecule therapies for solid tumors, today announced the closing of a Series A financing. The funds will be used to complete the pre-clinical development of Inthera's lead program against HPV-associated cancers and expand operations and pipeline.